Breaking News

Financial Report: Lilly

By Gil Roth | January 30, 2014

Cymbalta expiration begins to weigh down sales

Lilly 4Q13

4Q Revenues: $5.8 billion (-2%)

4Q Earnings: $728 million (-12%)

FY Revenues: $23.1 billion (+2%)

FY Earnings: $4.7 billion (+15%)

Comments: The U.S. patent for Cymbalta expired on Dec. 11, 2013, leading U.S. pharma revenues to fall 6% in 4Q13 to $3.0 billion. Cymbalta revenues dropped 38% in 4Q13 to $883 million, while sales in FY13 rose 2% to $5.1 billion. Zyprexa sales dropped 10% in 4Q13 to $348 million and fell 30% in FY13 to $1.2 billion. Humalog posted 19% growth in 4Q13 to $734 million, while Cialis rose 15% to $588 million during the quarter, both due to a mix of higher prices and increased volume. Net earnings fell 12% in 4Q13 as a result of lower operating income and a higher effective tax rate.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.